DEA Reviews Bulk Marijuana Making for Science Lab
Published Date: 3/27/2025
Notice
Summary
Ohana Bio Pharma, LLC wants to grow and make a lot of marijuana for science and medicine. The DEA is checking their application to make sure they follow the rules. If approved, this could help researchers get more marijuana for important studies, with no immediate cost changes announced.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
DEA review could increase research supply
If you are a researcher or research institution, Ohana Bio Pharma, LLC has applied to be registered by the Drug Enforcement Administration to manufacture marihuana in bulk as a Schedule I controlled substance for scientific and medical research. The DEA is evaluating the application under its registration program, and if approved researchers may gain increased access to research-grade marihuana. The notice does not announce any immediate changes to costs or prices.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-05276 — Bulk Manufacturer of Controlled Substances Application: Bulk Manufacturer of Marihuana: Baxter Research Lab
Baxter Research Lab wants to get official permission to grow and make large amounts of marijuana for science and medical research. The DEA is reviewing their application along with others to make sure they follow the rules. If approved, this could speed up important research without extra costs or delays.
Next: 2025-05278 — Importer of Controlled Substances Application: SpecGx LLC
SpecGx LLC wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs that are carefully regulated. If approved, it could affect businesses and agencies that work with these substances, with timing and costs depending on the registration process.